Skip to main content
NewslettersWatchlist

Gilead Sciences Inc(GILD-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low88.07
Day High89.94
Open:89.07
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
BayStreet.ca
Five Top Heart Health Stocks to Buy Heading into 2025
Barchart
Option Volatility And Earnings Report For November 11 - 15
Motley Fool
3 Spectacular High-Yield Dividend Stocks to Buy in November
Stock Target Advisor
Market News & Analysis: Nov 7th, 2024
MarketBeat
Gilead’s Stock Surge: What’s Fueling the Momentum?
Newswire.ca
GILEAD SCIENCES APPOINTS PAUL PETRELLI TO VICE PRESIDENT AND GENERAL MANAGER IN CANADA
Motley Fool
Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript
Barchart
S&P Futures Soar as Trump Wins U.S. Presidency, FOMC Meeting on Tap
Barchart
Option Volatility And Earnings Report For November 4 - 8
Barchart
Stocks Set for Muted Open With All Eyes on U.S. Presidential Election and Fed Meeting
Motley Fool
3 Absurdly Cheap Stocks That Pay High Dividends
Barchart
3 Top Healthcare Stocks to Buy for Growth and Dividends
Barchart
Covered Call Screener Results For October 17th
MarketBeat
Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Motley Fool
3 Dirt Cheap Stocks to Buy Right Now
Motley Fool
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Motley Fool
Why Gilead Sciences Stock Thrashed the Market Today
Barchart
Stocks Finish Higher on Economic Optimism
Barchart
Stocks Recover Early Losses on Supportive Corporate News
Barchart
Stocks Fall Back as Weakness in Chip Stocks Drag the Market Lower
Stock Target Advisor
Top Analyst Ratings & Analysis: Sept 4th 2024
The Globe and Mail
Seven U.S. dividend-payers to weather turbulent markets

Profile

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.